NasdaqGM - Delayed Quote USD

Silence Therapeutics plc (SLN)

19.75 -0.05 (-0.25%)

At close: October 30 at 4:00:00 PM EDT

Trade SLN on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for SLN

Previous Close 19.80
Open 19.74
Bid 7.92 x 200
Ask 14.22 x 200
Day's Range 19.74 - 19.80
52 Week Range 4.19 - 19.86
Volume 621,425
Avg. Volume 2,767,003
Market Cap (intraday) 1.229B
Beta (5Y Monthly) 1.45
PE Ratio (TTM) --
EPS (TTM) -1.29
Earnings Date (est.) Nov 5, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 19.75
Zacks Rating Bullish

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.

www.silence-therapeutics.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SLN

224.84%

S&P 500 (^GSPC)

10.73%

1-Year Return

SLN

170.18%

S&P 500 (^GSPC)

11.11%

3-Year Return

SLN

182.14%

S&P 500 (^GSPC)

81.91%

5-Year Return

SLN

10.19%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue --

Earnings -9.09M

Profit Margin 0.00%

FY25

FY26

-15M

-10M

-5M

-30000.0%

-20000.0%

-10000.0%

0.0%

Analyst Price Targets

19.00 Low

19.75 Average

19.75 Current

20.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 10/21/2026

Analyst HC Wainwright & Co.

Rating Action Downgrade

Rating Neutral

Price Action Lowers

Price Target 75 -> 20

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-29.65%
Return on Equity (ttm)

-90.41%
Revenue (ttm)

615k
Net Income Avi to Common (ttm)

-59.95M
Diluted EPS (ttm)

-1.29

Balance Sheet and Cash Flow

Total Cash (mrq)

72.05M
Total Debt/Equity (mrq)

0.29%
Levered Free Cash Flow (ttm)

-23.57M

BCYC Bicycle Therapeutics plc

3.6600 -4.19%

PHVS Pharvaris N.V.

33.53 -0.15%

INBX Inhibrx Biosciences, Inc.

71.78 -2.54%

KROS Keros Therapeutics, Inc.

11.04 -2.82%

LRMR Larimar Therapeutics, Inc.

2.4700 -7.49%

U.S. markets closed

Silence Therapeutics plc (SLN)

Trading disclosure

0.41%

80.70%

170.18%

224.84%

170.18%

-10.19%

1.28%

Silence Therapeutics plc Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch